INNOVATIVE TARGETING SOLUTIONS INC has a total of 27 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2009. It filed its patents most often in United States, Canada and EPO (European Patent Office). Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are ABCAM PLC, PRESTIGE BIOPHARMA PTE LTD and GENETASTIX CORP.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 9 | |
#2 | Canada | 6 | |
#3 | EPO (European Patent Office) | 6 | |
#4 | WIPO (World Intellectual Property Organization) | 5 | |
#5 | Australia | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Microorganisms | |
#3 | Analysing materials | |
#4 | Medical preparations | |
#5 | Therapeutic chemical compounds | |
#6 | Measuring microorganism processes | |
#7 | Combinatorial chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Kang Jaspal Singh | 27 |
#2 | Pigott Craig Robin | 27 |
#3 | Gallo Michael | 19 |
#4 | Lin Abby | 10 |
#5 | Gallo Michael Lajos | 8 |
#6 | Chai Falene | 5 |
#7 | Lin Abby Yu Chen | 4 |
Publication | Filing date | Title |
---|---|---|
CA3043263A1 | Chimeric receptors, biosensor host cells and methods/uses thereof | |
WO2017091905A1 | Single variable domain t-cell receptors | |
CA2932325A1 | G-protein coupled receptor agonists and methods | |
US2015240243A1 | Generating targeted sequence diversity in fusion proteins | |
CA2867231A1 | Generating targeted sequence diversity in proteins | |
CA2721231A1 | Sequence diversity generation in immunoglobulins |